Substandard Thyroxin Drugs Raise Safety Concerns In Sri Lanka
This article was originally published in PharmAsia News
Questions are being raised about transparency in Sri Lanka's handling of problem drugs in the wake of substandard thyroxin drugs reaching the market. Physicians are concerned the problems are not well-publicized or that substitute drugs can be questionable. Neither the thyroid pills behind the new concern nor their manufacturers were identified, although the drugs were said to have been imported by Sri Lanka's health system from India and the U.K., and that raw material had come from China and Germany. Some thyroxin has been withdrawn, others have been blacklisted, and the registration of others has been canceled. Physicians in private and state institutions have complained about the medicines. (Click here for more
You may also be interested in...
White House and HHS are increasing pressure on FDA Commissioner Hahn to clear Pfizer and Moderna’s COVID-19 vaccines as soon as possible – potentially skirting the advisory committee process. The move is leaving a last-minute political stain on a regulatory process the FDA fought hard to keep science-based and could foster a new wave of vaccine hesitancy amongst the American public.
Two physicians experienced in agency affairs and operations, former commissioner David Kessler and former principal deputy commissioner Joshua Sharfstein, are reportedly finalists to head Biden’s FDA.
Operation Warp Speed will hold back initial shipments to ensure two-dose regimens can be completed; 15 December is ‘chalk’ target date for emergency authorization of Pfizer vaccine, OWS’ Gustave Perna says, calling it only a projection that does not impinge on FDA authority. Sending only half shipments also eases burden on cold shortage capacity at state and local level, he says.